CA3022834A1 - Fulvestrant formulations and methods of their use - Google Patents
Fulvestrant formulations and methods of their use Download PDFInfo
- Publication number
- CA3022834A1 CA3022834A1 CA3022834A CA3022834A CA3022834A1 CA 3022834 A1 CA3022834 A1 CA 3022834A1 CA 3022834 A CA3022834 A CA 3022834A CA 3022834 A CA3022834 A CA 3022834A CA 3022834 A1 CA3022834 A1 CA 3022834A1
- Authority
- CA
- Canada
- Prior art keywords
- microns
- fulvestrant
- suspension
- pharmaceutical composition
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US62/332,842 | 2016-05-06 | ||
| US201662420555P | 2016-11-10 | 2016-11-10 | |
| US62/420,555 | 2016-11-10 | ||
| PCT/US2017/031376 WO2017193048A1 (en) | 2016-05-06 | 2017-05-05 | Fulvestrant formulations and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3022834A1 true CA3022834A1 (en) | 2017-11-09 |
Family
ID=58709642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022834A Pending CA3022834A1 (en) | 2016-05-06 | 2017-05-05 | Fulvestrant formulations and methods of their use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (enExample) |
| EP (1) | EP3452011A1 (enExample) |
| JP (3) | JP2019516789A (enExample) |
| KR (1) | KR102438425B1 (enExample) |
| CN (1) | CN109310621A (enExample) |
| AU (2) | AU2017261321B2 (enExample) |
| CA (1) | CA3022834A1 (enExample) |
| CO (1) | CO2018013257A2 (enExample) |
| IL (2) | IL285928B2 (enExample) |
| MA (1) | MA44862A (enExample) |
| MX (2) | MX2018013414A (enExample) |
| MY (1) | MY205661A (enExample) |
| UA (1) | UA125514C2 (enExample) |
| WO (1) | WO2017193048A1 (enExample) |
| ZA (1) | ZA201807031B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| BR112020009141A2 (pt) * | 2017-11-08 | 2020-10-27 | Eagle Pharmaceuticals, Inc. | método para tratar câncer de mama num indivíduo |
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| WO2022100750A1 (zh) * | 2020-11-16 | 2022-05-19 | 北京厚燊维康科技有限责任公司 | 可用于光动力治疗或诊断的制剂 |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| WO2023121232A1 (ko) * | 2021-12-20 | 2023-06-29 | 주식회사 삼양홀딩스 | 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| WO2001087262A2 (en) | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Stabilized steroidal suspension |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| EP1406662A1 (en) * | 2001-07-07 | 2004-04-14 | AstraZeneca AB | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| JP5513713B2 (ja) * | 2004-08-04 | 2014-06-04 | カムルス エービー | 非層状分散を生じる組成物 |
| CN101237857A (zh) | 2005-05-09 | 2008-08-06 | 生物领域医疗公司 | 使用微球和非离子型造影剂的组合物和方法 |
| EA015781B1 (ru) | 2005-10-21 | 2011-12-30 | Панацея Биотек Лимитед | Композиции для лечения рака |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| HRP20191104T1 (hr) | 2007-09-25 | 2019-09-20 | Solubest Ltd. | Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| EP2442789A1 (en) | 2009-06-18 | 2012-04-25 | Abbott Laboratories | Stable nanoparticulate drug suspension |
| US20130280330A9 (en) * | 2009-07-31 | 2013-10-24 | Xi'an Libang Medical Technology Co., Ltd. | Microsphere drug carrier, preparation method, composition and use thereof |
| CN102264372B (zh) * | 2009-08-31 | 2012-07-11 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| WO2012021791A2 (en) | 2010-08-13 | 2012-02-16 | Scidose Llc | Aqueous formulation with improved stability |
| CA2811258C (en) | 2010-09-16 | 2019-10-15 | Shimoda Biotech (Pty) Ltd | Fulvestrant compositions and methods of use |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| EP3925625A1 (en) | 2011-01-09 | 2021-12-22 | ANP Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| CA2836831C (en) * | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业（深圳）有限公司 | 资料存储器固定装置 |
| CA2869377C (en) | 2012-04-09 | 2022-11-08 | Scidose, Llc | Fulvestrant formulations |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| CN104379163A (zh) | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| WO2015033302A2 (en) * | 2013-09-06 | 2015-03-12 | Salah Uddin Ahmed | Fulvestrant compositions |
| US20160287601A1 (en) * | 2013-10-03 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Enhanced treatment regimens using pi3k inhibitors |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| WO2016004369A1 (en) | 2014-07-02 | 2016-01-07 | The Research Foundation For The State University Of New York | Surfactant-stripped micelle compositions with high cargo to surfactant ratio |
| CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 CA CA3022834A patent/CA3022834A1/en active Pending
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/en not_active Ceased
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/en active Pending
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017261321B2 (en) | 2023-03-09 |
| US20210346396A1 (en) | 2021-11-11 |
| CO2018013257A2 (es) | 2018-12-28 |
| MY205661A (en) | 2024-11-04 |
| RU2018142068A3 (enExample) | 2020-09-17 |
| US12370199B2 (en) | 2025-07-29 |
| BR112018072768A2 (pt) | 2019-02-19 |
| KR20190005183A (ko) | 2019-01-15 |
| JP2023109959A (ja) | 2023-08-08 |
| JP2019516789A (ja) | 2019-06-20 |
| RU2018142068A (ru) | 2020-06-08 |
| MX2018013414A (es) | 2019-06-06 |
| NZ747911A (en) | 2025-03-28 |
| ZA201807031B (en) | 2023-10-25 |
| AU2023203392A1 (en) | 2023-06-29 |
| KR102438425B1 (ko) | 2022-09-01 |
| US20190134059A1 (en) | 2019-05-09 |
| EP3452011A1 (en) | 2019-03-13 |
| MX2022013199A (es) | 2022-12-13 |
| IL262465A (en) | 2018-12-31 |
| IL285928B1 (en) | 2025-02-01 |
| UA125514C2 (uk) | 2022-04-13 |
| IL285928B2 (en) | 2025-06-01 |
| CN109310621A (zh) | 2019-02-05 |
| MA44862A (fr) | 2019-03-13 |
| AU2017261321A1 (en) | 2018-11-15 |
| IL285928A (en) | 2021-10-31 |
| JP7312523B2 (ja) | 2023-07-21 |
| JP2021169510A (ja) | 2021-10-28 |
| WO2017193048A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370199B2 (en) | Fulvestrant formulations and methods of their use | |
| JP2015521997A (ja) | ヒドロゲルワクチン調製物 | |
| ES2884849T3 (es) | Composiciones de profármaco de aripiprazol | |
| JP2012530694A (ja) | 薬物のナノ分散体およびその調製のための方法 | |
| CN105012236A (zh) | 一种长效非水载体注射液及其制备方法 | |
| WO2011047637A1 (zh) | 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法 | |
| Elsebay et al. | Nanosuspension: a formulation technology for tackling the poor aqueous solubility and bioavailability of poorly soluble drugs | |
| CN103405385B (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
| CN103263385A (zh) | 一种塞来昔布长效纳米注射剂及其制备方法 | |
| Tzachev et al. | Lipid nanoparticles at the current stage and prospects—A review article | |
| RU2775225C2 (ru) | Составы фульвестранта и способы их применения | |
| JP6826167B2 (ja) | アリピプラゾールプロドラッグ組成物 | |
| CN101132768A (zh) | 纳米颗粒他克莫司制剂 | |
| BR112018072768B1 (pt) | Suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa e suspensão fulvestrant aquosa | |
| HK40049829B (en) | Aripiprazole prodrug compositions | |
| RU2817019C2 (ru) | Композиции пролекарства арипипразола | |
| HK40049829A (en) | Aripiprazole prodrug compositions | |
| US20190365699A1 (en) | Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles | |
| HK1235285A1 (en) | Aripiprazole prodrug compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220413 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240823 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250616 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250616 |